RNS Number : 8115D
Fusion Antibodies PLC
11 May 2026

11 May 2026

Fusion Antibodies plc
("Fusion" or the **"Company")**

Grant of patent in Japan
Grant strengthens antibody discovery platform and licensing opportunities

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces the Company's patent application no. 2021-519644 has been formally granted by the Japan Patent Office (the "Japanese Patent Office") under Japanese Patent no. 7853096 (the "Patent").

The Patent, entitled "Antibody Library and Method", covers two families of antibodies, and the method for the design of such antibody libraries. The Patent is expected to be complementary to Fusion's offering to provide "Opti" designed antibody libraries for a range of applications including: Antibody Discovery; Affinity Maturation; and Sequence Optimisation.

The Company is also progressing additional patent applications in respect of the OptiMAL® Library in Japan and several other territories worldwide including Europe and China.

Richard Buick, CSO of Fusion, said: *"I am really pleased that the Japanese Patent Office has granted this approval. This confirms our unique approach to antibody library design and protects these families of antibodies. Furthermore with this recognition in Japan, we are continuing to advance our global strategy to expand the reach and impact of our Opti designed antibody technologies."*

Adrian Kinkaid, CEO of Fusion, said: *"This excellent news lays the foundations for potential future licensing deals and complements our strategy to protect OptiMAL®. This patent marks an important milestone in strengthening our platform and reinforces our commitment to delivering high quality antibody solutions for both therapeutic and diagnostic innovation. With this significant step, we are accelerating our mission to transform how antibodies are designed, discovered, and optimised worldwide."*

Enquiries:

Fusion Antibodies plc — www.fusionantibodies.com
Adrian Kinkaid, Chief Executive Officer — Via Walbrook PR
Stephen Smyth, Chief Financial Officer

Allenby Capital Limited — Tel: +44 (0)20 3328 5656
James Reeve/Vivek Bhardwaj (Corporate Finance)
Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking)

Shard Capital Partners LLP
Damon Heath (Joint Broker) — Tel: +44 (0)207 186 9952

Walbrook PR — Tel: +44 (0)20 7933 8780
or fusion@walbrookpr.com
Anna Dunphy — Mob: +44 (0)7876 741 001

Investor Hub
We encourage all investors to share questions on this announcement via our investor hub
https://investorhub.fusionantibodies.com/link/rJaa9e

About Fusion Antibodies plc

Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx ^{TM} platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and/or expressed over 750 antibodies and successfully completed over 250 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.

The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.

Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCSFFFSFEMSESI